About BeiGene (NASDAQ:BGNE)
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:BGNE
- CUSIP: N/A
- Web: www.beigene.com
- Market Cap: $3.35 billion
- Outstanding Shares: 39,820,000
- 50 Day Moving Avg: $92.21
- 200 Day Moving Avg: $92.21
- 52 Week Range: $26.43 - $118.95
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -16.84
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $6.42 per share
- Price / Book: 13.09
- EBITDA: ($179,280,000.00)
- Return on Equity: -65.85%
- Return on Assets: -49.40%
- Debt-to-Equity Ratio: 0.57%
- Current Ratio: 8.38%
- Quick Ratio: 8.38%
- Average Volume: 317,690 shs.
- Beta: -0.32
- Short Ratio: 3.93
Frequently Asked Questions for BeiGene (NASDAQ:BGNE)
What is BeiGene's stock symbol?
BeiGene trades on the NASDAQ under the ticker symbol "BGNE."
How were BeiGene's earnings last quarter?
BeiGene, Ltd. (NASDAQ:BGNE) posted its quarterly earnings results on Wednesday, March, 22nd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by $0.19. The firm earned $1 million during the quarter, compared to analyst estimates of $3.75 million. The company's quarterly revenue was down 78.6% on a year-over-year basis. During the same quarter last year, the firm earned ($3.05) earnings per share. View BeiGene's Earnings History.
When will BeiGene make its next earnings announcement?
Where is BeiGene's stock going? Where will BeiGene's stock price be in 2017?
6 brokerages have issued 12 month target prices for BeiGene's stock. Their forecasts range from $58.00 to $120.00. On average, they anticipate BeiGene's stock price to reach $88.00 in the next year. View Analyst Ratings for BeiGene.
What are analysts saying about BeiGene stock?
Here are some recent quotes from research analysts about BeiGene stock:
- 1. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (10/3/2017)
- 2. Maxim Group analysts commented, "BeiGene reported 1Q17 results. The company spent $52.5M during the quarter. The increased operating expenses were driven by clinical expansion to pivotal studies. Net loss for the quarter was $50.6M or ($1.27) per share. BeiGene ended the period with $327M of liquidity on the balance sheet. We model rising R&D expenses with clinical advances." (5/11/2017)
Who are some of BeiGene's key competitors?
Some companies that are related to BeiGene include Bioverativ (BIVV), bluebird bio (BLUE), TESARO (TSRO), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), AveXis (AVXS), GW Pharmaceuticals PLC (GWPH), Loxo Oncology (LOXO), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Prothena Corporation PLC (PRTA), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO) and Array BioPharma (ARRY).
Who are BeiGene's key executives?
BeiGene's management team includes the folowing people:
- John V Oyler, Chairman of the Board, Chief Executive Officer, Founder
- Howard Liang Ph.D., Chief Financial Officer and Chief Strategy Officer
- Wendy Yan, Senior Vice President, Head of Regulatory Affairs
- Jason Yang M.D.Suffix is Ph.D., Senior Vice President, Head of Clinical Development
- Timothy Y. Chen, Director
- Donald W. Glazer, Director
- Michael J. Goller, Director
- Ranjeev Krishana, Director
- Xiaodong Wang Ph.D., Director
When did BeiGene IPO?
(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.
Who owns BeiGene stock?
BeiGene's stock is owned by many different of institutional and retail investors. Top institutional investors include
BAKER BROS. ADVISORS LP
(5.60%). Company insiders that own BeiGene stock include Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, John Oyler, Ruirong Yuan, Thomas Malley and Xiaodong Wang. View Institutional Ownership Trends for BeiGene.
How do I buy BeiGene stock?
Shares of BeiGene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BeiGene's stock price today?
MarketBeat Community Rating for BeiGene (NASDAQ BGNE)MarketBeat's community ratings are surveys of what our community members think about BeiGene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of BeiGene stock can currently be purchased for approximately $84.03.
Consensus Ratings for BeiGene (NASDAQ:BGNE) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||6 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$88.00 (4.72% upside)|Consensus Price Target History for BeiGene (NASDAQ:BGNE)
Analysts' Ratings History for BeiGene (NASDAQ:BGNE)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/6/2017||Morgan Stanley||Reiterated Rating||Overweight||$87.00 -> $95.00||N/A|
|9/28/2017||Maxim Group||Reiterated Rating||Buy -> Buy||$77.00 -> $120.00||Low|
|8/15/2017||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Buy||$43.00 -> $86.00||Low|
|8/7/2017||Ladenburg Thalmann Financial Services||Initiated Coverage||Buy -> Buy||$81.00||High|
|7/6/2017||Robert W. Baird||Boost Price Target||Outperform||$44.00 -> $58.00||High|
|6/1/2017||William Blair||Reiterated Rating||Outperform||Low|
|10/7/2016||Cowen and Company||Reiterated Rating||Buy||N/A|
Earnings History for BeiGene (NASDAQ:BGNE)Earnings History by Quarter for BeiGene (NASDAQ BGNE)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/22/2017||Q4||($0.86)||($1.05)||$3.75 million||$1.00 million||View||N/A|
|8/10/2016||Q2||($0.68)||($0.73)||$2.08 million||$0.40 million||View||N/A|
|3/30/2016||Q4||($1.06)||($3.05)||$1.74 million||$4.68 million||View||N/A|
Earnings Estimates for BeiGene (NASDAQ:BGNE)
2017 EPS Consensus Estimate: ($3.91)
2018 EPS Consensus Estimate: ($4.60)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for BeiGene (NASDAQ:BGNE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for BeiGene (NASDAQ:BGNE)
Insider Ownership Percentage: 19.90%Insider Trades by Quarter for BeiGene (NASDAQ:BGNE)
Institutional Ownership Percentage: 51.02%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/11/2017||Bros. Advisors Lp Baker||Director||Buy||176,056||$71.00||$12,499,976.00|| |
|7/12/2017||Xiaodong Wang||Director||Sell||20,000||$72.44||$1,448,800.00|| |
|7/10/2017||Donald W Glazer||Director||Sell||10,810||$72.15||$779,941.50|| |
|7/6/2017||John Oyler||CEO||Sell||219,400||$64.82||$14,221,508.00|| |
|6/28/2017||Xiaodong Wang||Director||Sell||35,000||$44.95||$1,573,250.00|| |
|6/23/2017||John Oyler||CEO||Sell||98,500||$44.16||$4,349,760.00|| |
|6/2/2017||Xiaodong Wang||Director||Sell||5,539||$40.00||$221,560.00|| |
|5/4/2017||Xiaodong Wang||Director||Sell||14,461||$40.80||$590,008.80|| |
|5/1/2017||John Oyler||CEO||Sell||36,149||$40.47||$1,462,950.03|| |
|4/5/2017||Xiaodong Wang||Director||Sell||11,650||$36.83||$429,069.50|| |
|3/24/2017||Xiaodong Wang||Director||Sell||38,107||$36.96||$1,408,434.72|| |
|3/20/2017||John Oyler||CEO||Sell||31,989||$39.39||$1,260,046.71|| |
|3/10/2017||Xiaodong Wang||Director||Sell||36,892||$39.89||$1,471,621.88|| |
|3/6/2017||John Oyler||CEO||Sell||108,999||$40.91||$4,459,149.09|| |
|2/27/2017||Xiaodong Wang||Director||Sell||38,351||$38.19||$1,464,624.69|| |
|2/21/2017||John Oyler||CEO||Sell||64,963||$40.55||$2,634,249.65|| |
|11/23/2016||Thomas Malley||Director||Buy||30,000||$32.00||$960,000.00|| |
|11/18/2016||Bros. Advisors Lp Baker||Director||Buy||1,760,495||$32.00||$56,335,840.00|| |
|9/28/2016||Donald W Glazer||Director||Sell||41,463||$30.66||$1,271,255.58|| |
|9/27/2016||Donald W Glazer||Director||Sell||47,149||$29.61||$1,396,081.89|| |
|9/23/2016||Donald W Glazer||Director||Sell||36,443||$31.02||$1,130,461.86|| |
|9/21/2016||Donald W Glazer||Director||Sell||67,252||$31.42||$2,113,057.84|| |
|2/8/2016||Bros. Advisors Lp Baker||Director||Buy||1,912,680||$24.00||$45,904,320.00|| |
|2/8/2016||Howard Liang||CFO||Buy||65,000||$1.85||$120,250.00|| |
|2/8/2016||Ruirong Yuan||Insider||Buy||130,000||$1.85||$240,500.00|| |
Headline Trends for BeiGene (NASDAQ:BGNE)
Latest Headlines for BeiGene (NASDAQ:BGNE)
Loading headlines, please wait.
BeiGene (BGNE) Chart for Sunday, October, 22, 2017